Projects & Publications
Plataforma ISCIII de BioBancos y Biomodelos: Unidad Banco de Líneas Celulares de IDIBELL. PT23/00092. Instituto de Salud Carlos III. PI: Anna Veiga. 01/01/2024-31/12/2026. 226.954,00€
HAPLO-iPS: Generation of Human Induced Pluripotent Stem Cells from Haplo-Selected cord Blood samples. Cost Action (CA21151) Action Chair: Anna Veiga 2022-2026. 690.450€
Edición genómica mediante CRISPR/Cas9 en embriones humanos para el estudio del desarrollo embrionario temprano. (EMBRYOCRISPR) PI21/01122. Instituto de Salud Carlos III. IP: Anna Veiga. 01/01/2022-31/12/2024. 147.620,00 €
Plataforma de BioBancos y Biomodelos: Unidad integrada del Biobanco y del Banco de Líneas Celulares de IDIBELL BioCellBanK PT20/00171. Instituto de Salud Carlos III. Coordinator: Anna Veiga. 01/01/2021- 31/12/2023. 334.950,00€ (167.750,00€).
Puesta a punto de la metodología para la edición genómica CRISPR/Cas9 en embriones humanos para el estudio del desarrollo embrionario temprano (EMBRYOCRISPR). Fundación Merck Salud. PI: Anna Veiga (IDIBELL) 01/06/2020-30/05/2023. 30.000 €.
Edición genómica mediante CRISPR/Cas9 en embriones humanos para el estudio del desarrollo embrionario temprano (EMBRYOCRISPR). Sociedad Española de Fertilidad. IP: Anna Veiga (IDIBELL) 05/06/2020- 04/06/2022. 15.000 €.
Transplantation of human iPS cells-derived RPE cell suspension for Age Related Macular Degeneration (AMD). First-in man clinical trial.”. P-CMR[C] Expression of Interest. PI: Anna Veiga (IDIBELL) 01/01/2020-31/12/2020. 10.000€.
Carreras D, Martínez-Moreno R, Selga E, Roura,E Veiga A, Aran B, Kuebler B, Wangüemerth F, Brugada R, Scornika, F S, Guillermo J. Pérez GJ. Generation of three heterozygous and two homozygous hiPSC lines from a CPVT associated mutation RYR2_p.G357S from a large family of the Canary Islands Stem Cell Res 2026. 93:103959.
Kuebler B, Selvitella S, Aran B, Raya A, Veiga A. Deciphering reprogramming efficiency in human induced pluripotent stem cells: insights from the generation of 150 cell lines. Front Immunol 2026. 13:16:1719056.
Hägg A, Wood R, Mochizuki AL, Abberton K, Abranches E, Alvarez-Palomo B, Baptista R, Quintanilha Barbosa RA, Barry J, Carvalho AB, Bennaceur Griscelli A, Campos de Carvalho AC, Chaker D, Chang H, Choi HY, Codinach M, Arán Corbella B, Cowan S, Dickerson SJ, Elwood N, Fan X, Feyeux M, Forrester M, Gaffney A, Guilbert SM, Ha HY, Hirst AJ, Hunter AL, Jamieson LG, Judson RN, Kanemura Y, Kasai-Brunswick TH, Kim JH, Kim H, Kintali M, Krishnan S, Kuebler B, Lau CY, Li W, Mack A, MacLeod MR, Madrid M, Mamiya H, Manache-Alberici L, Mărginean D, Mentre O, Morgan SL, Mountford J, Munir H, Ng SHS, Ogawa H, Oh S, Ohara H, Oono K, Park N, Pereira LV, Pereira da Silva Bezerra I, Podovei AR, Querol S, Raje J, Raya A, Sakamoto S, Sarafian R, Schmit K, Selvitella S, Singh G, Smart MJK, Song J, Stacey G, Sullivan S, Sumida M, Terrenoire C, Tian P, Uhlin E, Vaquero JMA, Veiga A, Vicky Wang JW, Warre-Cornish K, Wood J, Yamamoto A, Zhang G, Hikichi T, Turner M, Falk A. Toward standardized iPSC testing: Insights from a multi-year international Quality Assessment Round. Stem Cell Rep 2026. 21(4):102857.
Catasús N, Casals-Sendra G,Torres-Martin M, Rosas I, Kuebler B, Mazuelas H, Amilibia E, Aran B, Veiga A, Raya A, Gel B, Blanco I, Serra E, Carrió M, Castellanos E. iPSC-based merlin-deficient Schwann cell-like spheroids as an in vitro system for studying NF2 pathogenesis. Genes & Diseases 2025. 12(6):101615.
Selvitella, S, Aran B, Veiga A, Kuebler B. Generation of the CTRL EiPS J9 mR6F-8 iPSC line derived from healthy human outgrowth blood endothelial cells (BOECs) using mRNA reprogramming methodology. Stem Cell Research 2024.81;103606.
Aran B, Morrow D, Rodriguez E, Veiga A. Unlocking the full potential of human induced pluripotent stem cells from haplo-selected cord blood samples—the how and the why. Cell & Gene Therapy Insights 2024. 10(1), 54–64.
Massafret O; Barragán M; Álvarez-González L; Aran B; Martín-Mur B; Esteve-Codina A, Ruiz-Herrera A, Vassena R , Ibañez E, Santaló J. The pluripotency state of human Embryonic Stem Cells derived from single blastomeres of eight-cell embryos. Cells Dev. 2024. 179. 203935.
Kuebler B; Alvarez-Palomo B; Aran B; Castaño J; Rodriguez L; Raya A, Querol Giner S, Veiga A. Generation of a bank of clinical-grade, HLA homozygous iPSC lines with high coverage of the Spanish population. Stem Cell Research & Therapy 2023. 14:366.
Martínez-Moreno R, Pérez-Serra A; Selga E; Carreras D; Aran B; Kuebler B; Scornik F et al. Generation of the induced pluripotent stem cell line ESi108-A from a familial atrial fibrillation patient. Stem Cell Res 2023. 73:103239.
Montero P, Flandes M, Kuebler B, Arán B, Larequi E, Anaut I, Coppiello G, Aranguren X, Veiga, A et al. Generation of an induced pluripotent stem cell line (ESi107-A) from a transthyretin amyloid cardiomyopahty (ATTR-CM) patient carrying a p. Ser43Asn mutation in the TTR gene. Stem Cell Res 2023. 71:103189.
Ávarez-Palomo, B, Veia A, Raya A, Codinach M, Torrents S, Ponce Verdugo L, Rodríguez-Aierbe C, Cuellar L, Alenda R, Arbona C, Hernández-Maraver D, Fusté C, Querol S. Public Cord Blood Banks as a source of starting material for clinical grade HLA-homozygous induced pluripotent stem cells Stem Cell Res Ther 2022. 13(1):408.
Martínez-Moreno R, Pérez-Serra A, Carreras D, Aran B, Kuebler B, Brugada R, Scornik FS, Pérez GJ, Selga E. Generation of an induced pluripotent stem cell line from a healthy Caucasian male. Stem Cell Res 2022. 60:102717.
Martínez-Moreno R, Carreras D, Aran B, Kuebler B, Sarquella-Brugada G, Brugada R, Perez GJ, Scornik F, Selga E. Generation of four induced pluripotent stem cell lines from a family harboring a single nucleotide variant in SCN5A. Stem Cell Research 2022. 63:102847.
Isla Magrané H, Veiga A, García Arumí J, Duarri A. Multiocular organoids from human induced pluripotent stem cells displayed retinal, corneal, and retinal pigment epithelium lineages. Stem Cell Res Ther. 2021 .12(1):581
Duarri A, Rodriguez-Bocanegra E, Martínez-Navarrete G, Biarnés M, García M, Lee Ferrano L, Kuebler B, Aran B, Izquierdo E, Aguilera-Xiol E, Casaroli-Merano RP, Trias E, Fernandez E, Ray A, Veiga A, Mones J. Transplantation of Human Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium in a Swine Model of Geographic Atrophy Int. J. Mol. Sci 2021. 22(19), 10497.
Maqueda M, Mosquera JL, García-Arumí J, Veiga A, Duarri. A. Repopulation of decellularized retinas with hiPSC-derived retinal pigment epithelial and ocular progenitor cells shows cell engraftment, organization and differentiation. Biomaterials 2021. 27;, 121049.
Álvarez-Palomo B, García-Martinez I, Gayoso J, Raya A, Veiga A, Abad ML, Eiras A, Guzmán-Fulgencio M, Luis-Hidalgo M, Eguizabal C, Santos S, Balas A, Alenda R, Sanchez-Gordo F, Verdugo LP, Villa J, Carreras E, Vidal F, Madrigal A, Herrero MJ, Rudilla F, Querol S. Evaluation of the Spanish population coverage of a prospective HLA haplobank of induced pluripotent stem cells .Stem Cell Res Ther 2021 .12(1):233.
Salas A, Duarri A, Fontrodona L, Ramirez DM, Badia A, Isla-Magrane H, Ferreira-de-Souza B, Zapata MA, Raya A, Veiga A, Garcia-Arumi J. Cell therapy with human induced pluripotent stem cell-derived retinal pigment epithelium and retinal precursor cells prevents visual function loss in a rat model of retinal degeneration. Mol Ther Methods Clin Dev 2021; 20: 688-702.
